The objective of this study was to explore the views and experiences of health care professionals with respect to the use of atypical antipsychotic (AAP) combination therapy and high-dose treatment strategies in adolescents and adults with schizophrenia.

Contents

• 1. INTRODUCTION
  • 1.1 COMPUS Expert Review Committee
• 2. ISSUE
  • 2.1 Schizophrenia
  • 2.2 Management of Schizophrenia
  • 2.3 Technology Description — Atypical Antipsychotics
• 3. OBJECTIVE
• 4. PROJECT OVERVIEW
• 5. RESEARCH QUESTIONS
• 6. METHODS
• 7. RESULTS
  • 7.1 Psychiatrists
  • 7.2 Family Physicians and General Practitioners
• 8. STRENGTHS AND LIMITATIONS
• 9. DISCUSSION
• APPENDIX 1 EXPERT COMMITTEE AND CONTRIBUTORS
• APPENDIX 2 MODERATOR’S GUIDE FOR CURRENT PRACTICE INTERVIEWS
• APPENDIX 3 QUOTES FROM PSYCHIATRISTS
• APPENDIX 4 QUOTES FROM FAMILY PHYSICIANS
• APPENDIX 5 ABBREVIATIONS
• REFERENCES

This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a comprehensive review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.

The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report

CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.

Production of this report is made possible through a financial contribution from Health Canada.